[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.153.63. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1987

Treatment of Experimental Granulomatous Uveitis by Lipoxygenase and Cyclo-oxygenase Inhibitors

Author Affiliations

From the Estelle Doheny Eye Foundation, Departments of Ophthalmology and Pathology (Drs Rao, Patchett, and Fernandez), Institute for Toxicology (Dr Sevanian), University of Southern California, Los Angeles; Department of Pathology, University of Michigan, Ann Arbor (Dr Kunkel); and Georgetown University, Washington, DC (Dr Marak).

Arch Ophthalmol. 1987;105(3):413-415. doi:10.1001/archopht.1987.01060030133043
Abstract

• Lens-induced granulomatous uveitis was produced in brown Norway rats. To determine the role of the lipoxygenase and cyclo-oxygenase products of arachidonic acid in the modulation of granulomatous uveitis, one group of experimental animals was treated with nafazatrom, while another group was treated with nordihydroguaiaretic acid (lipoxygenase inhibitors). Both resulted in significant attenuation of granulomatous inflammation, with reduced giant-cell infiltration into the choroid. In contrast, indomethacin (a cyclo-oxygenase inhibitor) therapy resulted in increased giant-cell formation. These findings suggest that the lipoxygenase and cyclo-oxygenase products of arachidonic acid play a role in the development of granulomatous uveitis and that such inflammation can be selectively suppressed by lipoxygenase inhibitors.

×